3rd Quarter - Termination

KOUNTOUPES DENHAM CARR & REID, LLC for GLENMARK PHARMACEUTICALS, INC., USA

Firm
Client
Income
$30,000
Expenses
—
Terminated
Aug 31, 2022

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

General education about the generic pharmaceutical industry.

Foreign entity interest: Glenmark Pharmaceuticals Inc. USA (GPI) is the North American division of Glenmark Pharmaceuticals, Ltd. (GPL), a corporation formed under the laws of India. GPL, as GPIs upstream foreign parent, has an interest in the listed issues.

LobbyistCovered position, as disclosed
ADAM HECHAVARRIA —
LISA KOUNTOUPES —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Pharmacy PHA

Issues related to affordability, essential medicine manufacturing, and pharmaceuticals. General issues related to H.R. 2853, the BLOCKING Act of 2021. Issues related to the Inflation Reduction Act (Public Law 117-169), focusing on pharmaceutical provisions.

Foreign entity interest: Glenmark Pharmaceuticals Inc. USA (GPI) is the North American division of Glenmark Pharmaceuticals, Ltd. (GPL), a corporation formed under the laws of India. GPL, as GPIs upstream foreign parent, has an interest in the listed issues.

LobbyistCovered position, as disclosed
ADAM HECHAVARRIA —
LISA KOUNTOUPES —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2853 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.